HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Supplement Market Enforcement Based On FDA Concerns, Not Discretion

Executive Summary

Although agency is prioritizing enforcement on hemp and CBD supplement and food products marketed with violative claims and allowing sales of products compliant with its regulations, the approach is not enforcement discretion, officials say. It's aware some companies are marketing hemp and CBD products "in ways that violate the law," and its "biggest concern" is products "that put the health and safety of consumers at greatest risk."

You may also be interested in...



CBD Supplement Label, Claim Violations Form Perfect Storm For Class Actions

"Technical" label violations, "full-spectrum" claims could spur class actions in CBD supplement space, says attorney Justin Prochnow. At Natural Products Expo East, he says numerous entrants have no experience and labels are likely targets as no standards are recognized for product and ingredient descriptions.

VMS Industry Wants Into CBD Market, Plus Enforcement On Firms Already There

FDA policy change making hemp and CBD eligible for use a dietary ingredients should include requiring regulatory compliance by companies already marketing products with the ingredients, representatives of firms and industry trade groups said at public hearing. Requirements include submitting to FDA pre-market notifications of proof of a reasonable expectation safety for an ingredient's intended use. "Ensure the rule of law is upheld by barring any company illegally marketing CBD or hemp-derived dietary ingredients from submitting an NDI for the period of time that their products have been illegally marketed," says NOW Health exec Aaron Secrist.

Legalizing Marijuana Would Calm CBD Regulatory Storm – CV Sciences' MacKay

As FDA moves slow on allowing CBD as a dietary ingredient, a marijuana reform law is a near-term possibility and would cause a “nuclear shift” about cannabis regulation and sway agency's decision, says cannabidiol firm CV Sciences executive.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS148829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel